|
|
| | 3-Morpholinemethanol, 4-[2-[2-[[3-(2-amino-6-chloro-4-pyrimidinyl)-1-(difluoromethyl)-1H-pyrazol-4-yl]methyl]phenoxy]ethyl]-, (3R)- Basic information |
| | 3-Morpholinemethanol, 4-[2-[2-[[3-(2-amino-6-chloro-4-pyrimidinyl)-1-(difluoromethyl)-1H-pyrazol-4-yl]methyl]phenoxy]ethyl]-, (3R)- Chemical Properties |
| Boiling point | 701.0±70.0 °C(Predicted) | | density | 1.49±0.1 g/cm3(Predicted) | | solubility | DMSO: Soluble | | pka | 14.85±0.10(Predicted) | | form | Solid | | color | White to off-white |
| | 3-Morpholinemethanol, 4-[2-[2-[[3-(2-amino-6-chloro-4-pyrimidinyl)-1-(difluoromethyl)-1H-pyrazol-4-yl]methyl]phenoxy]ethyl]-, (3R)- Usage And Synthesis |
| Uses | TDI-11861 is second-generation soluble Adenylyl Cyclase (sAC, ADCY10)inhibitorwith slow dissociation rates. TDI-11861 inhibits sAC cellular with an IC50 value of 5.5 nM[1]. | | References | [1] Miller M, et al. Design, Synthesis, and Pharmacological Evaluation of Second-Generation Soluble Adenylyl Cyclase (sAC, ADCY10) Inhibitors with Slow Dissociation Rates. J Med Chem. 2022 Nov 8. DOI:10.1021/acs.jmedchem.2c01133 [2] MELANIE BALBACH. On-demand male contraception via acute inhibition of soluble adenylyl cyclase.[J]. Nature Communications, 2023, 14 1: 637. DOI: 10.1038/s41467-023-36119-6 |
| | 3-Morpholinemethanol, 4-[2-[2-[[3-(2-amino-6-chloro-4-pyrimidinyl)-1-(difluoromethyl)-1H-pyrazol-4-yl]methyl]phenoxy]ethyl]-, (3R)- Preparation Products And Raw materials |
|